PREBIOTICS, PROBIOTICS, AND DIETARY FIBER

Clinical Nutrition in Gastrointestinal Disease

Volumn , Issue , 2024, Pages 123-138

  Floch, Martin H ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85206153890     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781003523086-13     Document Type: Chapter

References (153)

1. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiotia: introducing the concept of prebiotics. J Nutr. 1995;125: 1401-1412.
2. Crittenden RG. Prebiotics. In: Tannock GW, ed. Probiotics: A Critical Review. Wymondham, UK: Horizon Scientific Press; 1999: 141-156.
3. Cummings JH, Macfarlane GT, Englyst HN. Prebiotic digestion and fermentation. Am J Clin Nutr. 2001;73(Suppl): 415S-420S.
4. Rastall RA, Gibson GR. Prebiotic oligosaccharides: evaluation of biological activities and potential future developments. In: Tannock GW, ed. Probiotics and Prebiotics: Where Are We Going? Wymondham, England: Caister Academic Press; 2002: 107-148.
5. Ellegard L, Andersson H, Bosaeus I. Inulin and oligofructose do not influence the absorption of cholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, or bile acids but increases energy excretion in ileostomy subject. Eur J Clin Nutr. 1997: 51(1)1-5.
6. Cashman K. Prebiotics and calcium bioavailability. In: Tannock GW, ed. Probiotics and Prebiotics: Where Are We Going? Wymondham, England: Caister Academic Press; 2002: 149-174
7. Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of inulin and its hydrolysis products. J Nutr. 1998;128: 11-19.
8. Floch MH, Hong-Curtiss J. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr Treat Op in Gastro. 2003;6: 283-288.
9. Gibson GR, Beatty ER, Wang X. Cummings JH. Selective stimulations of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108: 975-982.
10. Macfarlane GT, Cummings JH. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ. 1999;318: 999-1003.
11. Ballongue J, Schumann C, Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand J Gastroenterol. 1997;32(Suppl): 222: 41-44.
12. Elkington SG, Floch MH, Conn HO. Lactulose in the treat-ment of chronic portal-systemic encephalopathy. N Engl J Med. 1969;281: 408-411.
13. Benno Y, Endo K, Shiragami N, et al. Effects of raffinose intake on human fecal microflora. Bifidobacteria Microflora. 1987;6: 59-63.
14. Hara T, Ikeda N, Hatsumi K, et al. Effects of small amount inges-tion of soybean oligosaccharides on bowel habits and fecal flora of volunteers. Jap J Nutr. 1997;55: 79-84 (In Japanese).
15. Klessen B, Sykura B, Zunfit HJ. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr. 1997;65: 1397-1402.
16. Olesen M, Gudmand-Hoyer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr. 2000;72(6): 1570-5.
17. Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr. 1999;129(7 Suppl): 1451S-3S.
18. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Design. 2003;9: 333-346.
19. Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcer-ative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Intern J Molec Med. 2003;12(5): 701-4.
20. Yamashita K, Kawai K, Itakura M. Effects of fructooligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res. 1984;4: 961-966.
21. Davidson MH, Maki KC, Synecki C, et al. Effects of dietary inulin on serum lipids in men and women with hypercholesterolemia. Nutr Res. 1998;18: 503-517.
22. Bukowska H. Pieczul-Mroz J, Jastrzebska M, et al. Decrease in fibrinogen and LDL-cholesterol levels upon supplementation of diet with Lactobacillus plantarum in subjects with moderately elevated cholesterol. Atherosclerosis. 1997;137: 437-8.
23. Naruszewicz M, Johansson M-L, Zapolska-Downar D, et al. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk fac-tors in smokers. Am J Clin Nutr. 2002;76: 1249-55.
24. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66: 365-378.
25. Metchnikoff E. The Prolongation of Life: Optimistic Studies. London: Butterworth-Heinemann; 1907.
26. Kipeloff N. Lactobacillus Acidophilus. Baltimore: Williams & Wilkins; 1926.
27. Rettger LF, Levy MN, Weinstein L, et al. Lactobacillus Acidophilus and Its Therapeutic Application. London: Yale University Press; 1935.
28. Freter R. The fatal enteric cholera infection in the guinea pig achieved by inhibition of normal enteric flora. J Infect Dis. 1955;97: 57-64.
29. Lilly DM, Stillwell RH. Probiotics: growth promoting factors pro-duced by micro-organisms. Science. 1965;147: 747-748.
30. Montrose D, Floch MH. Probiotics used in human studies. J Clin Gastroenterol. 2005;39: 469.
31. Sanders ME, Klaenhammer TR. The scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci. 2001;84: 319-331.
32. Floch MH, Hong-Curtiss J. Probiotics and functional foods in gas-trointestinal disorders. Curr Gastro Rep. 2001;3: 343-350.
33. Bernet MF, Brassart D, Nesser JR, et al. Lactobacillus acidophilus LA-1 binds to cultured human intestinal cell-lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35: 483-489.
34. Lidbeck A, Overnick E, Rafter J, et al. Effect of Lactobacillus aci-dophilus supplements on mutagen excretion in feces and urine in humans. Microb Ecol Health Dis. 1992;5: 59-67.
35. Salminen S, Deighton MA, Gorbach SL. Lactic acid bacteria in health and disease. In: von Wright SS, ed. Lactic Acid Bacteria. New York: Marcel Dekker; 1993: 199-225.
36. Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulatory antibody screening cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32: 141-144.
37. Kaila M, Isolauri E, Saxelin M, et al. Viable versus inactivated Lactobacillus GG in acute rotavirus diarrhea. Arch Dis Child. 1995;72: 51-53.
38. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bac-teria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1995;14: 107-111.
39. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol. 2000;95(suppl): S2-S4.
40. Marteau P. Flourie B, Pochart P, et al. Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans. Am J Clin Nutr. 1990;52: 685-688.
41. Shornikova A-V, Casas I, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24: 399-404.
42. Wolf BW, Garleb DG, Casas I. Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Microb Ecol Health Dis. 1995;8: 41-50.
43. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibi-otic associated diarrhea by Saccharomyces boulardi: a prospective study. Gastroenterology. 1989;96: 981-988.
44. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354: 635-9.
45. Nobaek S, Johansson M-L, Molin G, Ahrne S, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95: 1231-1238.
46. Hilton E, Isenberg HD Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med. 1992;116: 353-357.
47. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119: 305-309.
48. Mimura T, Rizzello F, Schreiber S, et al. Once daily high dose pro-biotic therapy maintains remission and improves quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial. Gastroenterology. 2002;122: A81.
49. McCracken UJ, Gasrins HR. probiotic and the immune system. In: Tannock GW, ed. Probiotics: A Critical Review. Norfolk, England: Horizon Scientific Press; 1999: 85-111.
50. Isolauri E, Sütas Y, Kankaapää P, et al. Probiotics: effects on immu-nity. Am J Clin Nutr. 2001;73(Suppl): 444S-450S.
51. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126: 1358-1373.
52. Sheil B, McCarthy J, O’Mahony L, et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut. 2004;53: 694-700.
53. Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (inflix-imab) to maintain remission in Crohn’s disease. Gastroenterology. 1999;117: 761-769.
54. Borruel N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor z production in Crohn’s disease can be downregu-lated ex vivo by probiotic bacteria. Gut. 2002;51: 659-664.
55. Mangell P, Nejdfors P, Wang M, et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci. 2002;47: 511-516.
56. Duggan C, Gannon J, Walker WA. Protective nutrients and functional foods for the gastrointestinal tract. Am J Clin Nutr. 2002;75: 789-808.
57. Hasler CM. Functional foods: benefits, concerns and challeng-es—a position paper from the American Council on Science and Health. Am Soc Nutr Sci. 2002;3772-3781.
58. Huang JS, Bousvaros A, Lee JW, et al. Efficacy of probiotic use in acute diarrhea in children. A meta-analysis. Dig Dis Sci. 2002; 47: 2625-2634.
59. Reid G. Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr. 2001;73(Suppl): 437S-443S.
60. McLean NW, Rosenstein IJ. Characterization and selection of a Lactobacillus species to re-colonise the vagina of women with recurrent bacterial vaginosis. J Med Microbiol. 2000;49: 543-552.
61. Furrie E, Macfarlane S, Cummings JH, Macfarlane GT. Systemic antibodies towards mucosal bacterial in ulcerative colitis and Crohn’s disease differentially activate the innate immune response. Gut. 2004;53: 91-98.
62. Schultsz C, Van Den Berg FM, Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999;117: 1089-1097.
63. Kleessen B, Koresen AJ, Buhr JH, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol. 2002;37: 1034-1041.
64. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the domi-nant feacal bacterial groups in patients with Crohn’s disease of the colon. Gut. 2003;52: 237-242.
65. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122: 44-54.
66. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remis-sion of ulcerative colitis. Aliment Pharmacol Ther. 1997;11: 853-858.
67. Kruis W, Kalk EK, Stolte M, et al. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology. 2001;120: A127.
68. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Amer Coll Nutr. 2003;22: 56-63.
69. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composi-tion of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharm and Ther. 1999;13: 1103-1108.
70. Karimi O, Pena AS, vanBodegraven AA. Probiotics (VSL#3) in arthralgia. Preliminary results of an ongoing open trial in patients with ulcerative colitis and Crohn’s disease. Gastroenterology. 2004;126: A-627.
71. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea-a pilot study. Z Gastroenterol. 1993;31: 129-134.
72. Guslandi M, Messi G, Sorghi M, Testoni PA. Saccharomyces bou-lardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45: 1462-1464.
73. Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrent of Crohn’s disease: a randomised controlled study versus mesalazine. Gastroenterology. 2000;118: A781.
74. Pantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease. A randomized controlled trial with Lactobacillus GG. Gut. 2002;51: 405-409.
75. Gionchetti P, Rizzello E, Ventoni A, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology. 2000;118: 1214.
76. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose pro-biotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53: 108-114.
77. Hart AL, Stagg A, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003;36: 111-119.
78. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13: 1143-7.
79. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diar-rhea-predominant irritable bowel syndrome. Alim Pharm Ther. 2003;17: 895-904.
80. O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis. 2000;32: 294-301.
81. Sen S, Mullan MM, Parker TJ, et al. Effect of Lactobacillus plan-tarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002;47: 2615-20.
82. Faber SM. Irritable bowel syndrome and reinoculation with probiotics. Am J Gastroenterol. 2002;97: A211.
83. Tannock GW. Probiotics: A Critical Review. Wymondham, UK: Horizon Scientific Press; 1999.
84. Cleave TL. The Saccharine Disease. New Canaan, CT: Keats Publishing, Inc.; 1975.
85. Burkett DP, Trowell HC. Refined Carbohydrate Foods and Disease: Some Implications of Dietary Fiber. London: Academic Press, 1975.
86. Burkett DP, Walker ARP, Painter NS. Dietary fiber and disease JAMA. 1974;229: 1068-1074.
87. Vahouny GV, Kritzhevsky D. Dietary Fiber. New York: Plenum Press; 1986.
88. Spiller GA. Dietary Fiber in Human Nutrition. 2nd ed. Boca Raton, FL: CRC Press, Inc.; 1993.
89. Trowell H, Burkett D, Heaton K. Dietary Fibre, Fibre-Depleted Foods and Disease. London: Academic Press; 1985.
90. Asp, N-GL. Classification and methodology of food carbohydrates as related to nutritional effects. Am J Clin Nutr. 1995;61(Suppl): 930S-7S.
91. Cummings JH, Englyst HN. Gastrointestinal effects of food carbo-hydrate. Am J Clin Nutr. 1995;61(Suppl) 938S-45S.
92. Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34: 362-6.
93. Ludwig DS, Eckel RH. The glycemic index at 20 y. Am J Clin Nutr. 2002;76(Suppl);264S-5S.
94. Foster-Powell K, Holt SHA, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr. 2002;76: 5-56.
95. Baig MM, Cerda JJ. Pectin: its interaction with serum lipoproteins. Am J Clin Nutr. 1981;34: 50-53.
96. Ross AHM, Eastwood MA, Anderson JR, et al. A study of the effects of dietary gum arabic in humans. Am J Clin Nutr. 1983;37: 368-375.
97. Jensen CD, Spiller GA, Gates JE, et al. The effect of acacia gum and a water-soluble dietary fiber mixture on blood lipids in humans. J Am Coll Nutr. 1993;12: 147-154.
98. Anderson JW, Story L, Sieling B, et al. Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr. 1984;40: 1146-1155.
99. Demark-Wahnefried W, Bowering J, Cohen PS. Reduced serum cholesterol with dietary change using fat-modified and oat bran supplemented diets. J Am Diet Assoc. 1990;90: 223-229.
100. Swain JF, Rouse IL, Curley CB, Sacks FM. Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. N Engl J Med. 1990;322: 147-152.
101. Cummings JH, Pomare EW, Branch WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28: 1221-1227.
102. Hoverstad T. Studies of short-chain fatty acid absorption in man. Scand J Gastroenterol. 1986;21: 257-260.
103. McNeil NI, Cummings JH, James WPT, et al. Short chain fatty acid absorption by the human large intestine. Gut. 1978;19: 819-822.
104. Roediger WEW. Role of anaerobic bacteria in the metabolic wel-fare of the colonic mucosa in man. Gut. 1980;21: 793-798.
105. Rabassa AA, Rogers AI. The role of short-chain fatty acid metabo-lism in colonic disorders. Am J Gastroenterol. 1992;87: 419-423.
106. Wolever TMS, Schrade KB, Vogt JA, et al. Do colonic short-chain fatty acids contribute to the long-term adaptation of blood lipids in subjects with type 2 diabetes consuming a high-fiber diet? Am J Clin Nutr. 2002;75: 1023-30.
107. Dorfman SH, Ali M, Floch MH. Low fiber content of Connecticut diets. Am J Clin Nutr. 1976;29: 87.
108. Anderson JW. Plant Fiber in Foods. Lexington KY: HCF Diabetes Research Foundation Inc.; 1986: 10-30.
109. Pennington JAT, Douglass JS. Bowes & Church’s Food Values of Portions Commonly Used. Philadelphia: Lippincott Williams & Wilkins; 2005.
110. Kromhout D, Bosschieter EB, Coulander, CdeL. Dietary fibre and 10-year mortality from coronary heart disease, cancer, and all causes. Lancet 1982;518-521.
111. Morris JN, Marr JW, Clayton DG. Diet and heart: a postscript. Br Med J. 1977;ii: 1307-14.
112. Pereira MA, O’Reilly E, Augustsson K, et al. Dietary fiber and risk of coronary heart disease. Arch Intern Med. 2004;164: 370-376.
113. Wu H, Dwyer KM, Fan Z, et al Dietary fiber and progression of atherosclerosis: the Los Angeles Atherosclerosis Study. Am J Clin Nutr. 2003;78: 1085-91.
114. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA. 1995;273: 1113-7.
115. Jenkins DJA, Newton AC, Leeds AR, Cummings JH. Effect of pectin, guar gum, and wheat fibre on serum cholesterol. Lancet. 1975;1: 116-117.
116. Olsen BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results for a meta-analysis. J Nutr. 1997;127: 1973-1980.
117. Anderson JW, Floore TL, Geil PB, et al. Hypocholesterolemic effects of different hydrophilic fibers. Arch Intern Med. 1991;151: 1597-602.
118. Jacobs Jr DR, Meyer KA, Kushi LH, Folsom AR. Whole-grain intake may reduce the risk of ischemic heart disease death in postmeno-pausal women: the Iowa Women’s Health Study. Am J Clin Nutr. 1998;68: 248-57.
119. Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consump-tion and decreased risk of sudden cardiac death in the physicians’ health study. Arch Intern Med. 2002;162: 1382-6.
120. Anderson JW, Randles KM, Kendall CWC, Jenkins DJA. Carbohydrate and fiber recommendations for individuals with dia-betes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004;23: 5-17.
121. Brand-Miller JC, Thomas M, Swan V, et al. Physiological valida-tion of the concept of glycemic load in lean young adults. J Nutr. 2003;133: 2728-2732.
122. Bolton RP, Heaton KW, Burroughs LF. The role of dietary fiber in satiety, glucose, and insulin: studies with fruit and fruit juice. Am J Clin Nutr. 1981;34: 211-217.
123. Cummings JH, Southgate DAT, Branch W, et al. Colonic response to dietary fibre from carrot, cabbage, apple, bran and guar gum. Lancet. 1978;1: 5-9.
124. Muir JG, Yeow EGW, Keogh J, et al. Combining wheat bran with resistant starch has more beneficial effects on fecal indexes than does wheat bran alone. Am J Clin Nutr. 2004;79: 1020-8.
125. Almy TP, Howell DA. Diverticular disease of the colon. N Engl J Med. 1980;302: 324-330.
126. Painter NS, Trowell H. Burkett DP, et al. Diverticular disease of the colon. In: Dietary Fibre, Fibre-Depleted Foods and Disease. London: Academic Press, 1985: 145-160.
127. Floch MH, Bina I. The natural history of diverticulitis: fact and theory. J Clin Gastroenterol. 2004;38(suppl): S2-S7.
128. Pohlman T. Diverticulitis. Gastroenterol Clin. 1988;17: 357-385.
129. Hughes LE. Postmortem survey of diverticular disease of the colon. Gut. 1969;10: 336-351.
130. Garcia G. Diverticulitis. In: Blaser MT, Smith DD, Ravdin JI, et al, eds. Infections of the Gastrointestinal Tract. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2002: 306-316.
131. Fisher N, Berry CS, Fearn T, et al. Cereal dietary fiber consumption and diverticular disease: a lifespan study in rats. Am J Clin Nutr. 1985;42: 788-804.
132. Patiner NS, Almeida AZ, Colebourn KW. Unprocessed bran in treatment of diverticular disease of colon. Br Med J. 1972;2: 137-140.
133. Findlay JM, Smith AN, Mitchell WD, et al. Effects of unprocessed bran on colon function in normal subjects and in diverticular disease. Lancet. 1974;1: 146-149.
134. Taylor, I, Duthie HL. Bran tablets and diverticular disease. Br Med J. 1976;1: 988-990.
135. Brodribb AJM. Treatment of symptomatic diverticular disease with high-fibre diet. Lancet. 1977;2: 664-666.
136. North WRS, Cox AG. Are fibre supplements really necessary in diverticular disease of the colon? a controlled clinical trial. Br Med J. 1981;282: 1353-1356.
137. Painter NS. Bran and the irritable bowel syndrome. Lancet. 1976;i: 540.
138. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994;344: 39-40.
139. Thun MJ, Calle EE, Namboodiri MM, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992;84: 1491.
140. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst. 1992;84: 1887.
141. Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology. 2000;118: 1235.
142. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst. 1995;87: 1760.
143. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamin C and E on rectal polyps in patients with familial adenomatous polyps. J Natl Cancer Inst. 1989;81: 1290-1297.
144. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain fatty acid irrigation. N Engl J Med. 1989;320: 23-27.
145. Roediger WEW, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp Path. 1986;67: 773-782.
146. Roediger WEW. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet. 1980;2: 712-715.
147. Scheppach W, Sommer H, Kirchner T, et al. Effect of butyr-ate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103: 51-56.
148. Scheppach W, German-Austrian SCFA Study Group. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. Dig Dis Sci. 1996;41: 2254-2259.
149. Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report. Dig Dis Sci. 1991;36: 185-187.
150. Patz J, Jacobsohn WZ, Gottschalk-Sabag S, et al. Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. Am J Gastroenterol. 1996;91: 731-734.
151. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcer-ative proctosigmoiditis with butyrate enemas. Am J Gastroenterol. 1994;89: 179-183.
152. Treem WR, Ashsan N. Shoup M. Hyams JS. Fecal short-chain fatty acids in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18: 159-164.
153. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo controlled trial. Gut. 1997;40: 485-491.